CCL2 is prognostic for hepatocellular carcinoma (HCC), where targeting TAMs via CCL2/CCR2 blockade effectively reduces tumour growth, reverses the immunosuppressive TME, and enhances cytotoxic T-cell responses58. This evidence concerns the gene CCR2 and neoplasm.